Current understanding of rheumatoid arthritis therapy

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 607-620

  Colmegna, I ^a   Ohata, B R ^b   Menard, H A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMG 108; AZATHIOPRINE; CANAKINUMAB; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ALLERGIC REACTION; ANEMIA; APLASTIC ANEMIA; ARTICLE; BONE MARROW TOXICITY; CONGESTIVE HEART FAILURE; CYTOPENIA; DEMYELINATING DISEASE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION; INTRACELLULAR SIGNALING; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LUPUS LIKE SYNDROME; MALAISE; MOUTH ULCER; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OPTIC NEURITIS; PANCYTOPENIA; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; TERATOGENESIS; VOMITING;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-6; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858795041     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.325     Document Type: Article

References (75)

1. Cope, A.P. T cells in rheumatoid arthritis. Arthritis Res. Ther. 10 (suppl. 1), S1 (2008).
2. Kitas, G.D. & Gabriel, S.E. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 70, 8-14 (2011).
3. Boonen, A. & Severens, J.L. The burden of illness of rheumatoid arthritis. Clin. Rheumatol. 30 (suppl. 1), S3-S8 (2011).
4. Klareskog, L., Catrina, A.I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659-672 (2009).
5. Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263-269 (2004). (Pubitemid 38942816)
6. Goekoop-Ruiterman, Y.P. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005). (Pubitemid 41612204)
7. Mease, P.J. Improving the routine management of rheumatoid arthritis: the value of tight control. J. Rheumatol. 37, 1570-1578 (2010).
8. Finckh, A., Liang, M.H., van Herckenrode, C.M. & de Pablo, P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 55, 864-872 (2006). (Pubitemid 44917458)
9. Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580-1588 (2010).
10. Guzian, M.C. et al. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies. Arthritis Care Res. (Hoboken). 62, 1624-1632 (2010).
11. Boire, G. et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res. Ther. 7, R592-R603 (2005).
12. Bykerk, V.P. et al. Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J. Rheumatol. (2011); e-pub ahead of print 15 September 2011.
13. Albani, S., Koffeman, E.C. & Prakken, B. Induction of immune tolerance in the treatment of rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 272-281 (2011).
14. Benson, R.A., Patakas, A., McQueenie, R., Ross, K., McInnes, I.B., Brewer, J.M. et al. Arthritis in space and time-to boldly go! FEBS. Lett. (2011); e-pub ahead of print 9 May 2011.
15. McInnes, I.B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429-442 (2007). (Pubitemid 46834849)
16. Rader, R.A. (Re)defining biopharmaceutical. Nat. Biotechnol. 26, 743-751 (2008). (Pubitemid 351961442)
17. Albrecht, K. & Muler-Ladner, U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin. Exp. Rheumatol. 28, S95-101 (2010).
18. Cronstein, B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163-172 (2005). (Pubitemid 41043882)
19. Wessels, J.A., Huizinga, T.W. & Guchelaar, H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 47, 249-255 (2008). (Pubitemid 351267187)
20. Spurlock, C.F. 3rd et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum. 63, 2606-2616 (2011).
21. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
22. Feldmann, M. & Maini, R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9, 1245-1250 (2003). (Pubitemid 37279838)
23. MacEwan, D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 14, 477-492 (2002). (Pubitemid 34230583)
24. Faustman, D. & Davis, M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493 (2010).
25. Cope, A.P. et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 35, 1160-1169 (1992).
26. Choy, E.H. & Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001). (Pubitemid 32224400)
27. Taylor, P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10, 308-315 (2010).
28. Gorman, C.L. & Cope, A.P. Immune-mediated pathways in chronic inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 22, 221-238 (2008). (Pubitemid 351606942)
29. Smolen, J.S. & Emery, P. Infliximab: 12 years of experience. Arthritis. Res. Ther. 13 Suppl 1, S2 (2011).
30. Tugwell, P., Singh, J.A. & Wells, G.A. Biologicals for rheumatoid arthritis. BMJ 343, d4027 (2011).
31. Singh, J.A., Wells, G.A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L., Macdonald, J.K.et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev., CD008794 (2011).
32. Keystone, E.C. Does anti-tumor necrosis factor-a therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J. Rheumatol. 38, 1552-1562 (2011).
33. Firestein, G.S., Alvaro-Gracia, J.M., Maki, R. & Alvaro-Garcia, J.M. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144, 3347-3353 (1990). (Pubitemid 20146364)
34. Ohshima, S. et al. Interleukin 6 plays a key role in the development of antigeninduced arthritis. Proc. Natl. Acad. Sci. USA 95, 8222-8226 (1998). (Pubitemid 28326094)
35. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
36. Jones, S.A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
37. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., M?ler-Newen, G. & Schaper, F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20 (2003). (Pubitemid 37046923)
38. Acosta-Rodriguez, E.V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007). (Pubitemid 47300008)
39. Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro-and antiinflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878-888 (2011).
40. Fava, R.A. et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 341-346 (1994). (Pubitemid 24181082)
41. Ferrara, N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36, 127-137 (1995).
42. Hashizume, M., Hayakawa, N. & Mihara, M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 47, 1635-1640 (2008).
43. Lubberts, E., Koenders, M.I. & van den Berg, W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7, 29-37 (2005). (Pubitemid 40214525)
44. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102, 783-788 (2003). (Pubitemid 36917762)
45. Lu, Z.Y., Brochier, J., Wijdenes, J., Brailly, H., Bataille, R. & Klein, B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22, 2819-2824 (1992).
46. Lu, Z.Y., Brailly, H., Wijdenes, J., Bataille, R., Rossi, J.F. & Klein, B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86, 3123-3131 (1995).
47. Fujimoto, M. et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58, 3710-3719 (2008).
48. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial. Arthritis Rheum. 50, 1761-1769 (2004). (Pubitemid 38725087)
49. Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N. & Kakehi, T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959-3964 (2008).
50. Weber, A., Wasiliew, P. & Kracht, M. Interleukin-1beta (IL-1beta) processing pathway. Sci. Signal. 3, cm2 (2010).
51. Dinarello, C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
52. Gabay, C., Lamacchia, C. & Palmer, G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232-241 (2010).
53. Mertens, M. & Singh, J.A. Anakinra for rheumatoid arthritis. Cochrane Database Syst. Rev. CD005121 (2009).
54. Hu, Y., Shen, F., Crellin, N.K. & Ouyang, W. The IL-17 pathway as a major therapeutic target in autoimmune diseases. Ann. NY Acad. Sci. 1217, 60-76 (2011).
55. Hueber, A.J. et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J. Immunol. 184, 3336-3340 (2010).
56. Kirkham, B.W. et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 54, 1122-1131 (2006). (Pubitemid 43672925)
57. Kastelein, R.A., Hunter, C.A. & Cua, D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242 (2007). (Pubitemid 46697908)
58. Duvallet, E., Semerano, L., Assier, E., Falgarone, G. & Boissier, M.C. Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 43, 503-511 (2011).
59. Palmer, G. & Gabay, C. Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7, 321-329 (2011).
60. Neumann, E., Frommer, K.W., Vasile, M. & Muler-Ladner, U. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum. 63, 1159-1169 (2011).
61. Klimiuk, P.A., Yang, H., Goronzy, J.J. & Weyand, C.M. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin. Immunol. 90, 65-78 (1999). (Pubitemid 29162185)
62. Mima, T. et al. Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J. Clin. Invest. 96, 1746-1758 (1995).
63. Kraan, M.C. et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 63, 483-488 (2004). (Pubitemid 38530189)
64. Weyand, C.M. & Goronzy, J.J. T-cell-targeted therapies in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 201-210 (2006).
65. Kremer, J.M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003). (Pubitemid 37409707)
66. Paust, S., Lu, L., McCarty, N. & Cantor, H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. USA 101, 10398-10403 (2004). (Pubitemid 38924937)
67. Schiff, M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 50, 437-449 (2011).
68. Buch, M.H. et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 68, 1220-1227 (2009).
69. Genovese, M.C. et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 63, 2854-2864 (2011).
70. Takemura, S., Klimiuk, P.A., Braun, A., Goronzy, J.J. & Weyand, C.M. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167, 4710-4718 (2001). (Pubitemid 32954353)
71. Engel, P., Gez-Puerta, J.A., Ramos-Casals, M., Lozano, F. & Bosch, X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol. Rev. 63, 127-156 (2011).
72. Cohen, S.B. Targeting the B cell in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 24, 553-563 (2010).
73. Kavanaugh, A. et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann. Rheum. Dis. 67, 402-408 (2008). (Pubitemid 351281278)
74. van Vollenhoven, R.F. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37, 558-567 (2010).
75. Bonilla-Hern, M.G., Miranda-Car M.E. & Martin-Mola, E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford) 50, 1542-1550 (2011).